

**ACI Formulations Limited**

**1st Quarter Report 2021-2022**


ACI Formulations Limited

Statement of financial position  
Unaudited


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2021	As at 30 June 2021
<b>Assets</b>			
Property, plant and equipment	5	2,363,817	2,372,942
Right-of-use assets		10,290	12,027
Investments	6	41,717	41,717
<b>Non-current assets</b>		<b>2,415,824</b>	<b>2,426,686</b>
Inventories	8	1,392,337	1,278,150
Trade receivables	9	1,291,841	1,284,540
Other receivables		52,655	48,147
Inter-company receivables	10	8,863	8,729
Advances, deposits and prepayments	11	38,542	48,882
Current tax assets		373,543	360,027
Cash and cash equivalents		141,269	191,034
<b>Current assets</b>		<b>3,299,050</b>	<b>3,219,509</b>
<b>Total assets</b>		<b>5,714,874</b>	<b>5,646,195</b>
<b>Equity</b>			
Share capital		450,000	450,000
Revaluation reserve		1,619,739	1,619,739
Retained earnings		992,385	939,636
<b>Total equity</b>		<b>3,062,124</b>	<b>3,009,375</b>
<b>Liabilities</b>			
Employee benefits	12	61,011	56,170
Deferred tax liabilities		30,899	36,696
Lease liabilities		6,150	7,340
<b>Non-current liabilities</b>		<b>98,060</b>	<b>100,206</b>
Bank overdrafts		189,116	107,334
Loans and borrowings		1,866,412	1,551,197
Lease liabilities- current portion		4,709	5,254
Trade payables		72,186	120,976
Other payables	13	414,377	398,396
Unclaimed Dividend	14	4,883	12,969
Inter-company payables	15	3,008	340,488
<b>Current liabilities</b>		<b>2,554,690</b>	<b>2,536,614</b>
<b>Total liabilities</b>		<b>2,652,750</b>	<b>2,636,820</b>
<b>Total equity and liabilities</b>		<b>5,714,874</b>	<b>5,646,195</b>
<b>Net asset value (NAV) per share</b>		<b>68.05</b>	<b>66.88</b>

  
Managing Director

  
Director

  
Chief Financial Officer


  
Company Secretary


ACI Formulations Limited


Statement of profit or loss and other comprehensive income  
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from	
		July 2021 to September 2021	July 2020 to September 2020
Revenue	16	1,019,826	846,272
Cost of sales	17	(734,101)	(626,861)
<b>Gross profit</b>		<b>285,725</b>	<b>219,411</b>
Other income		768	858
Administrative, selling and distribution expenses	18	(179,967)	(152,988)
<b>Operating profit</b>		<b>106,526</b>	<b>67,281</b>
<b>Finance costs, net</b>		<b>(30,395)</b>	<b>(39,386)</b>
<b>Profit before contribution to WPPF</b>		<b>76,131</b>	<b>27,895</b>
Contribution to WPPF		(3,807)	(1,395)
<b>Profit before tax</b>		<b>72,324</b>	<b>26,500</b>
Tax expenses		(19,575)	(7,502)
<b>Profit after tax</b>		<b>52,749</b>	<b>18,998</b>
Other comprehensive income		-	-
<b>Total comprehensive income</b>		<b>52,749</b>	<b>18,998</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)		1.17	0.42

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

**ACI Formulations Limited**  
**Statement of changes in equity**  
**Unaudited**

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2021			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2021</b>	450,000	1,619,739	939,636	3,009,375
<b>Total comprehensive income</b>				
Profit for the period	-	-	52,749	52,749
<b>Total comprehensive income</b>	-	-	52,749	52,749
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2021</b>	450,000	1,619,739	992,385	3,062,124

<i>In Taka</i>	For the 1st quarter ended 30 September 2020			
	Attributable to owner of the Company			Total
	Share capital	Revaluation reserve	Retained earnings	
<b>Balance at 1 July 2020</b>	450,000	1,136,393	820,348	2,406,741
<b>Total comprehensive income</b>				
Profit for the period	-	-	18,998	18,998
<b>Total comprehensive income</b>	-	-	18,998	18,998
<b>Transactions with owners of the company</b>				
<b>Contributions and distributions</b>				
Dividends	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-
<b>Balance at 30 September 2020</b>	450,000	1,136,393	839,346	2,425,739

**ACI Formulations Limited**

**Statement of cash flows  
Unaudited**

**Figures in "000"**


<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2021 to September 2021	July 2020 to September 2020
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,008,785	902,134
Cash paid to suppliers and employees		(1,061,885)	(941,235)
Cash (used in)/generated from operating activities		<b>(53,100)</b>	<b>(39,101)</b>
Interest paid		(9,510)	(18,110)
Income tax paid		(38,888)	(32,650)
		<b>(48,398)</b>	<b>(50,760)</b>
<b>Net cash (used in)/generated from operating activities*</b>	19	<b>(101,498)</b>	<b>(89,861)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(1,299)	(629)
<b>Net cash (used in)/generated from investing activities</b>		<b>(1,299)</b>	<b>(629)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(337,614)	(251,488)
Proceeds from loans and borrowings		315,215	257,822
Payment for lease liability		1,735	(2,078)
Dividends paid		(8,086)	(18)
<b>Net cash (used in)/generated from financing activities</b>		<b>(28,750)</b>	<b>4,238</b>
Net increase in cash and cash equivalents		<b>(131,547)</b>	<b>(86,252)</b>
Cash and cash equivalents as at 1 July		83,700	171,883
<b>Cash and cash equivalents as at 30 September</b>		<b>(47,847)</b>	<b>85,631</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		141,269	127,260
Bank overdraft		(189,116)	(41,629)
		<b>(47,847)</b>	<b>85,631</b>
<b>Net operating cash flow per share (NOCFPS)</b>		<b>(2.26)</b>	<b>(2.00)</b>

\* See Note 19 for reconciliation of net operating cash flow.


**ACI Formulations Limited**  
**Consolidated Statement of Financial Position**  
**Unaudited**


Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2021	As at 30 June 2021
<b>Assets</b>			
Property, plant and equipment	5(a)	2,364,732	2,373,950
Right-of-use assets		10,290	12,027
Investments	6(a)	37,769	37,769
Intangible assets	7	5,148	5,148
<b>Non-current assets</b>		<b>2,417,939</b>	<b>2,428,894</b>
Inventories	8(a)	1,392,337	1,278,151
Trade receivables	9(a)	1,292,857	1,285,524
Other receivables		52,680	48,146
Inter-company receivable	10(a)	575	741
Advances, deposits and prepayments	11(a)	39,194	49,567
Current tax assets		373,462	359,975
Cash and cash equivalents		142,520	191,829
<b>Current assets</b>		<b>3,293,625</b>	<b>3,213,933</b>
<b>Total assets</b>		<b>5,711,564</b>	<b>5,642,827</b>
<b>Equity</b>			
Share capital		450,000	450,000
Revaluation reserve		1,619,739	1,619,739
Retained earnings		987,845	935,071
<b>Equity attributable to the owner of the Company</b>		<b>3,057,584</b>	<b>3,004,810</b>
Non controlling interest		(117)	(118)
<b>Total equity</b>		<b>3,057,467</b>	<b>3,004,692</b>
<b>Liabilities</b>			
Employee benefits	12	61,011	56,170
Deferred tax liabilities		30,846	36,643
Lease liabilities		6,150	7,340
<b>Non-current liabilities</b>		<b>98,007</b>	<b>100,153</b>
Bank overdrafts		189,116	107,334
Loans and borrowings		1,866,412	1,551,197
Lease liabilities- current portion		4,709	5,254
Trade payables		72,950	121,742
Other payables	13(a)	415,012	398,998
Unclaimed Dividend	14	4,883	12,969
Inter-company payables	15	3,008	340,488
<b>Current liabilities</b>		<b>2,556,090</b>	<b>2,537,982</b>
<b>Total liabilities</b>		<b>2,654,097</b>	<b>2,638,135</b>
<b>Total equity and liabilities</b>		<b>5,711,564</b>	<b>5,642,827</b>
Net asset value (NAV) per share	20	67.95	66.77

  
 Managing Director

  
 Director

  
 Chief Financial Officer

  
 Company Secretary

ACI Formulations Limited


Consolidated statement of profit or loss and other comprehensive income  
Unaudited

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2021 to September 2021	July 2020 to September 2020
Revenue	16(a)	1,020,115	846,552
Cost of sales	17(a)	(734,101)	(626,861)
<b>Gross profit</b>		<b>286,014</b>	<b>219,691</b>
Other income		793	858
Administrative, selling and distribution expenses	18(a)	(180,062)	(153,083)
<b>Operating profit</b>		<b>106,745</b>	<b>67,466</b>
Finance costs, net		(30,559)	(39,455)
<b>Profit before contribution to WPPF</b>		<b>76,186</b>	<b>28,011</b>
Contribution to WPPF		(3,807)	(1,395)
<b>Profit before tax</b>		<b>72,379</b>	<b>26,616</b>
Income tax expenses		(19,604)	(7,517)
<b>Profit after tax</b>		<b>52,775</b>	<b>19,099</b>
<b>Other comprehensive income</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income</b>		<b>52,775</b>	<b>19,099</b>
<b>Total comprehensive income attributable to:</b>			
<b>Owners of the Company</b>		<b>52,774</b>	<b>19,097</b>
<b>Non controlling interest</b>		<b>1</b>	<b>2</b>
		<b>52,775</b>	<b>19,099</b>
<b>Earnings per share</b>			
Basic earnings per share (BEPS)	20	1.17	0.42

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity  
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2021					
	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2021</b>	450,000	1,619,739	935,071	3,004,810	(118)	3,004,692
<b>Total comprehensive income</b>						
Profit for the period	-	-	52,774	52,774	1	52,775
<b>Total comprehensive income</b>	-	-	52,774	52,774	1	52,775
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-	-	-
<b>Balance at 30 September 2021</b>	450,000	1,619,739	987,845	3,057,584	(117)	3,057,467
	For the 1st quarter ended 30 September 2020					
<i>In Taka</i>	Attributable to owner of the Company			Total	Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings			
<b>Balance at 1 July 2020</b>	450,000	1,136,393	815,586	2,401,979	(122)	2,401,857
<b>Total comprehensive income</b>						
Profit for the period	-	-	19,097	19,097	2	19,099
<b>Total comprehensive income</b>	-	-	19,097	19,097	2	19,099
<b>Transactions with owners of the company</b>						
<b>Contributions and distributions</b>						
Dividends	-	-	-	-	-	-
<b>Total transactions with owners of the company</b>	-	-	-	-	-	-
<b>Balance at 30 September 2020</b>	450,000	1,136,393	834,683	2,421,076	(120)	2,420,956



**ACI Formulations Limited**  
**Consolidated statement of cash flows**  
**Unaudited**

Figures in "000"

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2021 to September 2021	July 2020 to September 2020
<b>Cash flows from operating activities</b>			
Cash received from customers and others		1,009,066	902,547
Cash paid to suppliers and employees		(1,061,822)	(941,235)
Cash (used in)/generated from operating activities		<b>(52,756)</b>	<b>(38,688)</b>
Interest paid		(9,674)	(18,178)
Income tax paid		(38,888)	(32,649)
		<b>(48,562)</b>	<b>(50,827)</b>
<b>Net cash (used in)/generated from operating activities*</b>	<b>19 (a)</b>	<b>(101,318)</b>	<b>(89,515)</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(1,299)	(629)
<b>Net cash (used in)/generated from investing activities</b>		<b>(1,299)</b>	<b>(629)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(337,339)	(251,833)
Proceeds from loans and borrowings		315,216	257,822
Payment for lease liability		1,735	(2,078)
Dividends paid		(8,086)	(18)
<b>Net cash (used in)/generated from financing activities</b>		<b>(28,474)</b>	<b>3,893</b>
Net increase in cash and cash equivalents		<b>(131,091)</b>	<b>(86,251)</b>
Cash and cash equivalents as at 1 July		<b>84,495</b>	<b>172,575</b>
<b>Cash and cash equivalents as at 30 September</b>		<b>(46,596)</b>	<b>86,324</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		142,520	127,953
Bank overdraft		(189,116)	(41,629)
		<b>(46,596)</b>	<b>86,324</b>
<b>Net operating cash flow per share (NOCFPS)</b>	<b>20</b>	<b>(2.25)</b>	<b>(1.99)</b>

\* See Note 19(a) for reconciliation of consolidated net operating cash flow.

**ACI Formulations Limited**

**Notes to the financial statements  
as at and for the 1st quarter ended on 30 September 2021  
Unaudited**

**1 Company profile:**

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

**2 Subsidiaries of ACI Formulations Limited:**

ACI Formulations Limited has one subsidiary namely Neem Laboratories (Pvt.) Ltd, engaged in manufacturing and marketing of herbal products . ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

**3 Consolidated Financial statements:**

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

**4 Selected explanatory notes:**

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2021. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

		<u>Figures in '000'</u>	
		<u>30- Sep -21</u>	<u>30-June -21</u>
		<u>Taka</u>	<u>Taka</u>
<b>5</b>	<b>Property, plant &amp; equipment</b>		
	Opening balance	2,696,085	2,179,120
	Addition during the period/year	1,299	516,965
		<u>2,697,384</u>	<u>2,696,085</u>
	Accumulated depreciation at the end of period/year	<u>(333,567)</u>	<u>(323,143)</u>
	<b>Closing balance</b>	<u><u>2,363,817</u></u>	<u><u>2,372,942</u></u>
<b>5(a)</b>	<b>Consolidated property, plant &amp; equipment</b>		
	Opening balance	2,701,045	2,184,080
	Addition during the period/year	1,299	516,965
		<u>2,702,344</u>	<u>2,701,045</u>
	Accumulated depreciation at the end of period/year	<u>(337,612)</u>	<u>(327,095)</u>
	<b>Closing balance</b>	<u><u>2,364,732</u></u>	<u><u>2,373,950</u></u>

	<u>30- Sep -21</u>	<u>30-June -21</u>
	<u>Taka</u>	<u>Taka</u>
<b>6 Investments</b>		
Investment in subsidiaries	3,948	3,948
Investment in FDR	37,694	37,694
Investment in shares of ACI Motors Limited	75	75
	<u>41,717</u>	<u>41,717</u>
<b>6(a) Consolidated investments</b>		
Investment in FDR	37,694	37,694
Investment in Shares- ACI Motors Limited	75	75
	<u>37,769</u>	<u>37,769</u>
<b>7 Intangible assets</b>		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
<b>8 Inventories</b>		
Raw and packing materials	700,445	608,708
Finished goods	597,057	619,749
Goods in transit	116,609	54,801
Other inventories	24,576	25,307
Allowances for slow moving inventory	(46,350)	(30,415)
	<u>1,392,337</u>	<u>1,278,150</u>
<b>8(a) Consolidated inventories</b>		
Raw and packing materials	700,445	608,708
Finished goods	597,333	620,026
Goods in transit	116,609	54,801
Other inventories	24,576	25,307
Allowances for slow moving inventory	(46,626)	(30,691)
	<u>1,392,337</u>	<u>1,278,151</u>
<b>9 Trade receivables</b>		
Related parties	-	-
Other than related parties	1,499,814	1,490,542
	<u>1,499,814</u>	<u>1,490,542</u>
Allowances for doubtful debts	(207,973)	(206,002)
	<u>1,291,841</u>	<u>1,284,540</u>
Below six months	1,058,879	1,031,873
Over six months	440,935	458,669
Allowances for doubtful debts	(207,973)	(206,002)
	<u>1,291,841</u>	<u>1,284,540</u>
<b>9(a) Consolidated trade receivables</b>		
Related parties	-	-
Other than related parties	1,500,830	1,491,526
	<u>1,500,830</u>	<u>1,491,526</u>
Allowances for doubtful debts	(207,973)	(206,002)
	<u>1,292,857</u>	<u>1,285,524</u>
Below six months	1,059,895	1,032,857
Over six months	440,935	458,669
Allowances for doubtful debts	(207,973)	(206,002)
	<u>1,292,857</u>	<u>1,285,524</u>

	<u>30- Sep -21</u> <u>Taka</u>	<u>30-June -21</u> <u>Taka</u>
<b>10 Inter-company receivables</b>		
Neem Laboratories (Pvt.) Ltd.	8,863	8,729
	<u>8,863</u>	<u>8,729</u>
<b>10(a) Consolidated inter-company receivables</b>		
ACI Limited	575	741
	<u>575</u>	<u>741</u>
<b>11 Advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staffs	81	261
Suppliers & others	21,940	30,686
VAT current account	(713)	(442)
	<u>21,308</u>	<u>30,505</u>
<b>Deposits:</b>		
Security deposits	9,810	9,640
Bank guarantee margin	4,784	4,784
	<u>14,594</u>	<u>14,424</u>
<b>Prepayments:</b>		
Prepaid expenses	2,640	3,953
	<u>2,640</u>	<u>3,953</u>
	<u>38,542</u>	<u>48,882</u>
<b>11(a) Consolidated advances, deposits &amp; prepayments</b>		
<b>Advances:</b>		
Staff	81	261
Suppliers & others	22,592	31,372
VAT current account	(713)	(442)
	<u>21,960</u>	<u>31,191</u>
<b>Deposits:</b>		
Security deposits	9,810	9,640
Bank guarantee margin	4,784	4,784
	<u>14,594</u>	<u>14,424</u>
<b>Prepayments:</b>		
Prepaid expenses	2,640	3,953
	<u>2,640</u>	<u>3,953</u>
	<u>39,194</u>	<u>49,567</u>
<b>12 Employee benefits</b>		
Defined benefit obligation	46,902	42,490
Other employee benefits	14,109	13,680
	<u>61,011</u>	<u>56,170</u>
<b>13 Other payables</b>		
Creditor for expenses	323,365	333,416
Advance from customer	-	1,467
Interest payable	41,454	20,568
Security money payable	22,321	21,466
Withholding tax and VAT payable	8,143	6,192
Workers' profit participation fund	19,094	15,287
	<u>414,377</u>	<u>398,396</u>

	<u>30- Sep -21</u> <u>Taka</u>	<u>30-June -21</u> <u>Taka</u>
<b>13(a) Consolidated other payables</b>		
Creditor for expenses	323,797	333,844
Advance from customer	-	1,467
Interest payable	41,454	20,568
Security money payable	22,321	21,466
Withholding tax and VAT payable	8,346	6,366
Provision for workers' profit participation fund	19,094	15,287
	<u>415,012</u>	<u>398,998</u>
<b>14 Unclaimed dividend account</b>		
Unclaimed/ unpaid dividend	4,883	12,969
	<u>4,883</u>	<u>12,969</u>
<b>15 Inter-company payables</b>		
ACI Limited	3,008	340,488
	<u>3,008</u>	<u>340,488</u>

	<u>for the period from</u>	
	<u>July 2021 to</u> <u>September 2021</u> <u>Taka</u>	<u>July 2020 to</u> <u>September 2020</u> <u>Taka</u>
<b>16 Revenue</b>		
Crop Care & Public Health	815,853	636,709
Mosquito Coil	11,821	6,305
Aerosol	117,504	126,631
Paint	61,472	71,022
Others	13,176	5,605
	<u>1,019,826</u>	<u>846,272</u>
<b>16(a) Consolidated revenue</b>		
Crop Care & Public Health	815,853	636,709
Mosquito Coil	11,821	6,305
Aerosol	117,504	126,631
Paint	61,472	71,022
Others	13,465	5,885
	<u>1,020,115</u>	<u>846,552</u>

		for the period from	
		July 2021 to	July 2020 to
		September 2021	September 2020
		Taka	Taka
<b>17</b>	<b>Cost of sales</b>		
	Opening stock	1,228,458	1,127,866
	Purchase	752,201	734,530
	Stock write off	935	4,212
		<u>1,981,594</u>	<u>1,866,608</u>
	Closing stock	(1,297,502)	(1,287,204)
		<u>684,092</u>	<u>579,404</u>
	Manufacturing expenses	50,009	47,457
		<u>734,101</u>	<u>626,861</u>
<b>17(a)</b>	<b>Consolidated cost of sales</b>		
	Opening stock	1,228,734	1,128,142
	Purchase	752,201	734,530
	Stock write off	935	4,212
		<u>1,981,870</u>	<u>1,866,884</u>
	Closing stock	(1,297,778)	(1,287,480)
		<u>684,092</u>	<u>579,404</u>
	Manufacturing expenses	50,009	47,457
		<u>734,101</u>	<u>626,861</u>
<b>18</b>	<b>Administrative, selling and distribution expenses</b>		
	Administrative expenses	38,160	30,094
	Distribution expenses	27,648	26,166
	Selling expenses	114,159	96,728
		<u>179,967</u>	<u>152,988</u>
<b>18(a)</b>	<b>Consolidated administrative, selling and distribution expenses</b>		
	Administrative expenses	38,255	30,189
	Distribution expenses	27,648	26,166
	Selling expenses	114,159	96,728
		<u>180,062</u>	<u>153,083</u>
<b>19</b>	<b>Reconciliation of net operating cash flow</b>		
		for the period from	
		July 2021 to	July 2020 to
		September 2021	September 2020
<i>In Taka</i>			
	Profit after tax	52,749	18,998
	Adjustment for non cash items and others:		
	- Depreciation and amortization	10,424	13,026
	- Provisions	3,185	3,237
	- Net finance cost	20,886	21,276
	- Tax expense	(19,313)	(25,148)
	- Contribution to WPPF	3,806	1,395
	Changes in:		
	- Inventories	(115,120)	(128,930)
	- Trade and other receivables	(13,780)	55,084
	- Advances, deposit and prepayments	10,341	(32,244)
	- Trade and other payables, employment benefits <sup>1</sup>	(54,676)	(16,555)
	Cash generating from operating activities	<u>(101,498)</u>	<u>(89,861)</u>

19 (a)

**Reconciliation of consolidated net operating cash flow**

<i>In Taka</i>	for the period from	
	July 2021 to September 2021	July 2020 to September 2020
Profit after tax	52,775	19,099
Adjustment for:		
- Depreciation and amortization	10,517	13,119
- Bad debts and inventory loss/(recovery)	3,185	3,237
- Net finance cost	20,886	21,276
- Tax expense	(19,284)	(25,132)
- Contribution to WPPF	3,806	1,395
Changes in:		
- Inventories	(115,120)	(128,930)
- Trade and other receivables	(13,837)	55,217
- Advances, deposit and prepayments	10,401	(32,244)
- Trade and other payables, employment benefits'	(54,647)	(16,552)
Cash generating from operating activities	(101,318)	(89,515)

**20 Consolidated EPS, NAV per Share and NOCFPS:**

	for the period upto	
	July 2021 to September 2021	July 2020 to September 2020
Weighted average number of ordinary shares (in thousand)	45,000	45,000
Consolidated profit attributable to equity holders of the Company (Taka '000)	52,774	19,097
Earnings per share (Taka)	1.17	0.42
Consolidated cash flows from operating activities (Taka '000)	(101,318)	(89,515)
Net operating cash flows per share (NOCFPS)	(2.25)	(1.99)
	<b><u>30- Sep -21</u></b>	<b><u>30-June -21</u></b>
	<b><u>Taka</u></b>	<b><u>Taka</u></b>
Consolidated net asset attributable to equity holders of the	3,057,584	3,004,810
Net asset value (NAV) per share	67.95	66.77

Consolidated revenue increased by around 21% over SPLY mainly due to higher sales in CC&PH business and Contract Manufacturing Activity. Higher sales alongwith changes in product mix in CC&PH business, led to increase overall gross profit by 30% over SPLY whereas overall operating expenses increased by 17.6% . In addition to that, lower financing cost mainly due to lower interest rate and efficient & effective utilization of working capital through optimized inventory and receivable management led to higher consolidated profit after tax of Tk. 52.78 Mn against Tk 19.10 Mn of SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS decreased due to inventory build-up for upcoming 2nd quarter .

## 21 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

**Crop Care and Public Health (CC & PH)** To manufacture and sell crop care and public health products.

**Mosquito Coil (M Coil)** To manufacture and sell mosquito coil products

**Aerosol** To manufacture and sell aerosol and air freshener products.

**Paint** To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on		1st quarter ended on	
	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	815,853	636,709	11,821	6,305	109,418	84,617	61,472	71,022	13,176	5,605	1,011,740	804,258
Inter-segment revenues	-	-	-	-	8,086	42,014	-	-	289	280	8,375	42,294
Total revenue	815,853	636,709	11,821	6,305	117,504	126,631	61,472	71,022	13,465	5,885	1,020,115	846,552
Financing costs	(25,749)	(34,003)	-	-	-	-	(4,357)	(5,071)	(454)	(381)	(30,559)	(39,455)
Depreciation	(4,744)	(5,629)	(3,522)	(4,618)	(1,065)	(1,310)	(931)	(1,267)	(254)	(294)	(10,517)	(13,119)
Cost of sales excluding depreciation	(538,900)	(423,793)	(19,959)	(14,584)	(106,393)	(118,794)	(48,540)	(54,839)	(12,815)	(5,922)	(726,607)	(617,932)
Operating expenses excluding depreciation	(143,031)	(114,527)	(1,901)	(1,885)	(1,956)	(1,292)	(30,149)	(30,739)	(3)	(451)	(177,040)	(148,894)
Other income /(expense)	590	676	-	-	49	13	130	169	25	-	793	858
<b>Profit before tax</b>	<b>98,818</b>	<b>56,461</b>	<b>(12,884)</b>	<b>(14,043)</b>	<b>7,732</b>	<b>4,985</b>	<b>(21,256)</b>	<b>(19,688)</b>	<b>(31)</b>	<b>(1,099)</b>	<b>72,379</b>	<b>26,616</b>
<b>Reportable segment assets</b>	<b>2,567,261</b>	<b>2,546,825</b>	<b>648,303</b>	<b>669,250</b>	<b>682,108</b>	<b>630,937</b>	<b>466,109</b>	<b>441,967</b>	<b>1,347,783</b>	<b>1,353,848</b>	<b>5,711,564</b>	<b>5,642,827</b>
<b>Reportable segment liabilities</b>	<b>1,629,365</b>	<b>1,672,648</b>	<b>11,410</b>	<b>8,885</b>	<b>176,633</b>	<b>131,879</b>	<b>127,329</b>	<b>98,844</b>	<b>709,361</b>	<b>725,879</b>	<b>2,654,097</b>	<b>2,638,135</b>

\* Comparative figures of segment assets and segment liabilities are as of 30 June 2021.

22 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.